Each year, more than 1 million pati...

Each year, more than 1 million patients are admitted to U hospitals because of unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). To help standardize the assessment and treatment of these patients, the American guild of Cardiology and the American Heart Association conven a task force to formulate a management guideline. This guideline, which was published in 2000 and updated in 2002 highlights latter medical advances and is a practical tool to help physicians provide medical care for patients with UA/NSTEMI. Management of suspected UA/NSTEMI has four components: initial evaluation and management; hospital care; coronary revascularization; and hospital discharge and post-hospital care. Part I of this two-part article discusses the first sum of two units components of management. During the initial evaluation, the history, physical examination, electrocardiogram, and cardiac biomarkers are used to determine the likelihood that the patient has UA/NSTEMI and to aid in risk assessment when the diagnosis is established. Hospital care consists of appropriate initial triage and monitoring. Medical treatment includes anti-ischemic therapy (oxygen nitroglycerin, beta blocker) antiplatelet therapy (aspirin, clopidogrel, platelet glycoprotein IIb/IIIa inhibitor), and antithrombotic therapy (heparin, low-molecular-weight heparin). (Am Fam Physician 2004;70:525-32 Copyright [c] 2004 American Academy of Family Physicians.)

The time "acute coronary syndrome" encompasses unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) and elevation myocardial infarction (STEMI). UA/NSTEMI is the combination of pair closely related clinical entities (i.e., a syndrome) whereas STEMI is a distinct clinical entity. UA/NSTEMI is characterized by means of an imbalance between myocardial oxygen furnish and demand. Most often, the syndrome discloses because of decreased myocardial perfusion resulting from coronary narrowing caused according to nonocclusive thrombus formation subsequent to disruption of an atherosclerotic plaque. In contrast, STEMI deductions from an occlusive thrombus.

Each year, more than 5 million patients not past nor future to U.S. emergency departments with chest pain and related symptoms. (1) Approximately 14 million of these patients are admitted for management of UA/NSTEMI. (1) Because of the end of the problem, it is important for family physicians to under-stand the diagnosis, risk assessment, and treatment of this syndrome

To help standardize the assessment and treatment of patients with UA/NSTEMI, the American association of Cardiology (ACC) and the American Heart Association (AHA) conven a task force to bring into view a management guideline. The ACC/AHA guideline, which was published in 20001 and updated in 2002 (23) divides the management of suspected UA/NSTEMI into four components: initial evaluation and management; hospital care; coronary revascularization; and hospital discharge and post-hospital care. This two-part article focuses upon the major management recommendations in the guideline, using the ACC/AHA classification of recommendations (Table 1) (3) novel advances in management are highlighted. Part I reviews the first pair components of management, and part II (4) reviews the other sum of two units components.

Initial Evaluation and Management

sum of two units important issues arise in the initial evaluation of the patient with a suspected acute coronary syndrome: the likelihood that the clinical presentation exhibits an acute coronary syndrome (Table 2) (35) and the risk of adverse out-come (Table 3) (35) The initial clinical evaluation to address the pair issues should include a history, a physical examination, an electrocardiogram, and a cardiac biomarker measurement (a cardiac-specific troponin on a level [preferred in the ACC/AHA guideline (23)] or an MB isoenzyme of creatine kinase level) Data from this evaluation aid in the assessment of risk and in decisions about the required intensity of monitoring (intensive care unit versus "step-down" unit), choice of therapeutic agents, and use of cardiac catheterization and revascularization.

RISK PREDICTION RULE

The 2002 ACC/AHA guideline (23) includes the use of a risk prediction authority for early assessment. Multiple risk scores have been cause to growed to predict the likelihood of adverse issues in patients presenting with UA/NSTEMI. (6-8) individual example is the seven-point Thrombolysis in Myocardial Infarction (TIMI) risk score for UA/NSTEMI (Figure 1) (6)

The TIMI risk score integrates historical factors, oftenness of symptoms, electrocardiographic findings, and cardiac biomarker horizontals (6) Higher scores are associated with an increased risk of adverse results such as death, (re)infarction, or renewed ischemia requiring revascularization. The risk of these issues ranges from approximately 5 percent with a TIMI risk score of cipher or one point to approximately 41 percent with a risk score of six or seven points. The risk score may be used to help guide therapeutic decisions. Patients with higher risk scores have been shown to derive greater benefit from specific pharmacologic therapies (enoxaparin Lovenox], (6) platelet glycoprotein IIb/IIIa inhibitor (9)) and an early cardiac catheterization (invasive) strategy. (10)